Andreas Jenne

Dr. Andreas Jenne is co-founder and managing director of NEO New Oncology, a molecular diagnostics company recently acquired by Siemens Healthineers. Prior to joining NEO New Oncology, he worked in various management positions in the biotechnology sector. From 2000 to 2005, he was the CEO of a NascaCell, a biotech company focusing on drug discovery services. Andreas then founded the proteomics company Kinaxo specializing in the development of targeted cancer drugs using chemical proteomics technologies. After selling Kinaxo to Evotec, he served there as Executive Vice President of the Biomarkers division. Andreas holds a Ph.D. in Chemistry from the Maximilians-University in Munich.